Intralesional Measles, Mumps, and Rubella Vaccine Versus Intralesional Candida Antigen in the Treatment of Common and Plantar Warts

2021 ◽  
pp. 120347542199113
Author(s):  
Ahmad Nofal ◽  
Reda Ezz El-arab ◽  
Mohamed Nasr ◽  
Rania Alakad
Keyword(s):  
Therapeutic Response ◽  
Comparable Efficacy ◽  
Efficacy And Safety ◽  
Mmr Vaccine ◽  
Rubella Vaccine ◽  
Complete Clearance ◽  
Common Warts ◽  
The Difference ◽  
Plantar Warts

Background Intralesional immunotherapy has been effectively used in the treatment of warts; however, comparative studies between different antigens are limited. Objective To evaluate the efficacy and safety of intralesional measles, mumps, and rubella (MMR) vaccine compared with intralesional Candida antigen for the treatment of multiple common and plantar warts. Methods Sixty-eight adult patients with multiple common and plantar warts were randomly assigned into two groups, each containing 34 patients. The first group received intralesional MMR vaccine, while the second group received intralesional Candida antigen. Each treatment was injected into the largest wart at 2-week intervals until complete clearance or for a maximum of 5 sessions. Results The overall therapeutic response was higher in the Candida antigen group (73.5%) compared with the MMR group (67.7%); however, the difference was not statistically significant. Complete clearance of common warts was higher in the Candida antigen group, while that of plantar warts was higher in the MMR group. Adverse effects were transient and well tolerated in both groups. No recurrence was detected during the 6-month follow-up period. Conclusion Intralesional MMR and intralesional Candida antigen showed comparable efficacy and safety in the treatment of common and plantar warts.

Successful Treatment of Plantar Warts with Very Diluted Bleomycin Using a Translesional Multipuncture Technique: Pilot Prospective Study

2012 ◽  
Vol 16 (4) ◽  
pp. 250-256 ◽  
Author(s):  
Khalid M. Alghamdi ◽  
Huma Khurram
Keyword(s):  
Side Effects ◽  
Injection Technique ◽  
Complete Clearance ◽  
Low Concentration ◽  
The Mean ◽  
High Concentrations ◽  
Multiple Treatments ◽  
Plantar Warts

Background: Plantar warts are common and often painful. Treatment of plantar warts is difficult and requires multiple treatments. Several clinical trials have proven the efficacy of bleomycin, but relatively high concentrations have been required and considerable side effects have been experienced. Objective: To evaluate the efficacy and safety of low-concentration (0.1 U/mL) bleomycin using a translesional injection technique for the treatment of plantar warts. Methods: The study included 23 patients with single or multiple plantar warts. Very low-concentration bleomycin was injected into a single wart or the largest plantar wart in the case of multiple lesions. Injections were performed at 4-week intervals until resolution of the warts or development of side effects. The translesional multipuncture technique was used. Results: Thirteen patients were male (56.5%), and the mean age was 27.7 years. The results revealed complete clearance of warts in 17 of 23 (74%) patients, partial response in 1 (4.3%) patient, and no response in 3 (13%) patients. Recurrence was observed in 2 patients at 3 months of follow-up. Among those two, one patient showed complete clearance after the second injection at 6 months of follow-up. All patients were followed for 6 months after the initial treatment. No significant long-term adverse effects were noted. Only three patients (13%) had localized moderate pain for 2 to 3 days after the injection. Conclusion: Translesional injection by very low-concentration (0.1 U/mL) bleomycin appears to be a simple, effective, and safe treatment modality for plantar warts.

Intralesional Vitamin D Injection May Be an Effective Treatment Option for Warts

2015 ◽  
Vol 20 (2) ◽  
pp. 118-122 ◽  
Author(s):  
Habibullah Aktaş ◽  
Can Ergin ◽  
Betül Demir ◽  
Özlem Ekiz
Keyword(s):  
Vitamin D ◽  
Candida Albicans ◽  
Adverse Effects ◽  
Effective Treatment ◽  
Treatment Option ◽  
Complete Resolution ◽  
Efficacy And Safety ◽  
Effective Treatment Option ◽  
Rubella Vaccine ◽  
Plantar Warts

Background: Plantar warts are typically resistant to treatment. In recent years, treatments have included administration of intralesional tuberculin; measles, mumps, rubella vaccine; and Candida albicans antigen immunotherapy. To the best of our knowledge, there are no reports of intralesional vitamin D administration for the treatment of warts. Aim: To evaluate the efficacy and safety of intralesional vitamin D treatment for plantar warts. Methods: Twenty patients with single or multiple plantar warts were included in this study. Vitamin D3 (0.2 mL, 7.5 mg/mL) was injected into the base of the warts after prilocaine (0.1 mL, 20 mg/mL) injection. A maximum of 5 warts were treated in 1 session, with at maximum 2 injections performed at 4-week intervals. Results: In total, 16 of 20 patients (80%) showed complete resolution of warts, and 1 patient showed partial resolution. Three patients failed to show any response. No recurrence or serious adverse effects were observed. Conclusion: Intralesional vitamin D3 may be an effective treatment option for warts.

scholarly journals MyoRing Implantation in Comparison with MyoRing Implantation Combined with Corneal Collagen Crosslinking for Keratoconus

2019 ◽  
Vol 16 (1S) ◽  
pp. 85-90
Author(s):  
G. M. Kazakbaeva
Keyword(s):  
Corneal Thickness ◽  
Efficacy And Safety ◽  
Collagen Crosslinking ◽  
Corrected Visual Acuity ◽  
Number Of Patients ◽  
Significant Difference ◽  
Corneal Collagen Crosslinking ◽  
The Difference ◽  
Corneal Collagen

Purpose: tо estimate the effectiveness of complete corneal ring (MyoRing) implantation compared with MyoRing implantation combined with corneal collagen crosslinking (CXL) for keratoconus treatment for 36 months follow-up. Patients and Methods. There were 101 patients (124 eyes) with progressing keratoconus aged 18–59 years in the study. Intracorneal rings were implanted in all patients. The patients were divided into 2 groups. MyoRing implantation was performed in a series of 59 patients (76 eyes) with keratoconus II–III Amsler classification, 42 patients (48 eyes) had MyoRing implantation combined with CXL. Implantation of a MyoRing in the corneal pocket was performed using a PocketMaker microkeratome and corneal intrastromal implantation system. Results. Keratometry was reduced in both groups; after MyoRing implantation for 8,45 D and MyoRing combined with CXL for 7,44 D, the spherical equivalent decreased for 7,72 and 6,29 D respectively, after 36 months. The cylinder decreased to 3,33 D with MyoRing alone and to 3,11 D with MyoRing combined with CXL. The smallest corneal thickness remained stable during 36 months after the procedure. There was an improvement in uncorrected and corrected visual acuity, and the difference in the CRF within the period of up to 12 months after the operation. It can be explained by the pseudochase formation in the group with a combined procedure. Conclusion. The implantation of the MyoRing IRC and the combination of MyoRing with CXL showed efficacy and safety in stabilizing keratoconus stabilization, as well as correction of comorbided ametropia 3 years after surgery. Both MyoRing implantation and MyoRing combined with CXL were effective in the stabilization of progressive keratoconus, as well as the correction of ametropia 3 years after surgery. There was no significant difference in MyoRing implantation and its combination with corneal crosslinking in visual and refractive results. The refractive power of the cornea was only one exeption. Long follow-up and randomized prospective studies with a large number of patients are needed.

scholarly journals Ustekinumab in Real-Life Practice: Experience in 116 Patients with Moderate-To-Severe Psoriasis

2019 ◽  
Vol 32 (3) ◽  
pp. 214 ◽  
Author(s):  
Inês Raposo ◽  
Andreia Bettencourt ◽  
Luiz Leite ◽  
Manuela Selores ◽  
Tiago Torres
Keyword(s):  
Therapeutic Response ◽  
Life Experience ◽  
Real Life ◽  
Severe Psoriasis ◽  
Secondary Treatment ◽  
Efficacy And Safety ◽  
Biologic Therapies ◽  
Response Data ◽  
Practice Experience

Introduction: Ustekinumab is a monoclonal antibody directed against the p40 subunit common to both IL-12 and IL-23 cytokines. Although the evidence of ustekinumab efficacy and safety in clinical trials is extensively recognized, data on its use in clinical practice is limited. Our objective is to report on the real-life experience of two Portuguese dermatology departments with ustekinumab in patients with moderate to severe psoriasis, and to identify the clinical characteristics associated with a weaker clinical response.Material and Methods: Clinical, demographic, and therapeutic response data was retrospectively collected in 116 patients with moderate to severe psoriasis treated with ustekinumab between November 2009 and December 2015.Results: A PASI75 therapeutic response was observed in 67.2%, 85.3%, 89.6% and 88.7% of patients at weeks 4, 12, 24 and 52, respectively. Ustekinumab was discontinued in seven patients (three due to primary failure, three due to secondary treatment failure, and one due to adverse events). Neither cardiovascular events nor cases of reactivation of previous infections (tuberculosis, hepatitis B) were observed during follow-up. In nine patients methotrexate was used as adjuvant therapy, and fourteen patients required ustekinumab dosage optimization. No side effects were observed in the two latter groups. The therapeutic response was higher in patients naïve to biologic therapies as compared to non-naïve patients.Discussion and Conclusion: A trend towards lower clinical response was observed in patients weighing between 90-100 kg, and dosage optimization in this group of patients may be of value prior to considering biologic switch.

Efficacy and safety of endostar in the treatment of advanced lung squamous cell carcinoma.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. e20574-e20574
Author(s):  
Weiheng Hu ◽  
Jian Fang ◽  
Jun Nie ◽  
Ling Dai ◽  
Jie Zhang ◽  
...  
Keyword(s):  
Group Versus ◽  
Lung Squamous Cell Carcinoma ◽  
Progression Free Survival ◽  
Control Group ◽  
Efficacy And Safety ◽  
Free Survival ◽  
Treatment Groups ◽  
The Difference ◽  
Nsclc Patients

e20574 Background: From the early 2000s, many advances in non-small cell lung cancer (NSCLC) have been made with the emergence of targeted therapies. However, because of safety concerns and a lower prevalence of relevant therapeutic targets, patients with squamous NSCLC have been excluded from many of these breakthroughs. Endostar is a novel inhibitor of tumor angiogenesis that acts specifically on neovascular endothelial cells. This study is to explore the clinical efficacy and safety of endostar in advanced squamous NSCLC patients. Methods: We performed a retrospective analysis of 259 newly diagnosed advanced squamous NSCLC patients who had received platinum-based doublet chemotherapy (PBDC) between September 2009 and March 2016. Of these patients, 116 received Endostar combined with PBDC, and 143 received PBDC only. Clinical tumor responses, progression-free survival (PFS), overall survival (OS), and toxicity profiles were recorded and analyzed. Results: After a median follow-up of 13.5 months, a improvement in PFS was observed in the Endostar group, the median PFS was7.7 months compared with 5.4 months in the control group (HR, 0.745; P= 0.034). The median OS was 19.0 months in the Endostar group versus 14.3 months in the control group, but the difference was not significant (HR, 0.780; P= 0.094). Multivariate analysis demonstrated that in patients with advanced squamous NSCLC, anti-angiogenesis therapy with Endostar, radiotherapy of primary tumor and Ⅲb stage were significant and independent predictors of improved PFS ( P< 0.05). For both arms, hematologic and gastrointestinal toxicities were the most common adverse events. Patients treated with Endostar had slightly higher rates of cardiac disorder and thromboembolic event, as compared with the control patients, but there were no statistically significant differences in toxicities overall between the 2 treatment groups. Conclusions: The current study indicates that Endostar as an anti-angiogenesis therapy combined with PBDC is able to provide further survival benefits with satisfactory toxicity in previously untreated squamous NSCLC patients, which merits further evaluation in randomized trials.

scholarly journals Intralesional Measles Mumps Rubella vaccine versus BCG in the treatment of multiple cutaneous warts: a comparative study

2021 ◽  
Vol 12 (e) ◽  
pp. e82-e82
Author(s):  
Gopal Nayana ◽  
Nirvanappa Vinay ◽  
H R Umadevi ◽  
M R Suresh ◽  
Nagesha Parvathi
Keyword(s):  
Comparative Study ◽  
Global Assessment ◽  
Therapeutic Response ◽  
Group 14 ◽  
Rubella Vaccine ◽  
Complete Clearance ◽  
Assessment Scores ◽  
Significant Difference ◽  
Cutaneous Warts

Background: Verrucae or warts are benign epithelial proliferations that occur due to accumulation of keratinocytes induced by HPV. Immunotherapy is a new promising modality which uses the principle of activation of one’s own immunity against the disease. Materials and methods: The study included 40 patients with multiple cutaneous warts in two groups of 20 each. Assigned treatment was injected into the single largest wart at an interval of 3 weeks until complete clearance or for a maximum of 3 times. Results: A statistically significant difference (p=0.018) was seen in the therapeutic response when compared to that of the BCG. All 20(100%) patients in the MMR group showed >50% clearance while in the BCG group 14(70%) patients showed >50% clearance according to Physician’s Global Assessment scores. Conclusions: Intralesional immunotherapy with MMR and BCG vaccines are both safe and promising whereas the therapy with MMR stands out with statistically significant results.

scholarly journals Intralesional Bleomycin for the Treatment of Resistant Palmoplantar and Periungual Warts

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Suchana Marahatta ◽  
Dhan Keshar Khadka ◽  
Sudha Agrawal ◽  
Arpana Rijal
Keyword(s):  
Retrospective Study ◽  
Side Effects ◽  
Treatment Response ◽  
Efficacy And Safety ◽  
Poor Treatment ◽  
Systemic Side Effects ◽  
The Mean ◽  
Plantar Warts ◽  
Poor Treatment Response

Introduction. Periungual, palmar, and plantar warts are difficult to treat with poor treatment response. Intralesional (IL) bleomycin has shown promising results for their treatment in a few reports. However, we need further evidence before opting it for treating difficult sites and resistant warts. Hence, we conducted this study to assess the efficacy and safety of IL bleomycin for the treatment of resistant palmoplantar and periungual warts. Methods. In this retrospective study, we included all patients who were given IL bleomycin for warts over a year. Maximum three sittings of bleomycin (1 mg/ml) were given monthly, and they were followed up for 3 months after the procedure. The response was categorized as complete, near-complete, significant, moderate, mild, and no clearance for 100%, 75–99%, 50–74%, 25–49%, 1–25%, and 0% clearance, respectively. Results. Out of 29 patients, follow-up details were available only in 19 patients (53 warts). The mean duration was 2.5 ± 1.47 years. The number of past interventions ranged from 2–4. Wart clearance after the first intervention was complete in 36.84%, near-complete in 26.31%, significant in 26.31%, and moderate in 10.53%. Wart clearance after the last intervention was complete in 89.47% and near-complete in 10.52% of patients. However, during 3 months of follow-up after the last injection, 15.78% had a recurrence. None of them had severe local and systemic side effects. Conclusions. IL bleomycin could be a better treatment option for the treatment of resistant and difficult warts. However, we observed a higher recurrence rate even in a shorter follow-up. Hence, we need further studies with larger samples.

scholarly journals Relative efficacy and safety of intralesional measles mumps rubella vaccine (MMR) and intralesional vitamin D in multiple and recalcitrant verrucae vulgaris

2021 ◽  
Vol 7 (2) ◽  
pp. 158-163
Author(s):  
SK Malhotra ◽  
Niharika Mittal ◽  
Navyug Raj Singh
Keyword(s):  
Vitamin D ◽  
Relative Efficacy ◽  
Efficacy And Safety ◽  
Mmr Vaccine ◽  
Rubella Vaccine ◽  
Papilloma Virus ◽  
Verrucae Vulgaris ◽  
Group A ◽  
Grade Ii ◽  
Group B

Verrucae or Warts are the viral infection of skin and mucosae caused by Human Papilloma Virus (HPV). Destructive modalities are the mainstay of treatment. They can have their own shortcomings like pain, infection, scarring and recurrence. To overcome these, immunotherapy is the emerging modality. To study the relative efficacy and safety of intralesional Measles Mumps Rubella (MMR) vaccine and intralesional Vitamin D in the treatment of multiple and recalcitrant verruca vulgaris. 50 patients with multiple (&#62;5) and recalcitrant warts were enrolled and divided randomly into two groups (Group A and Group B): In Group A, 25 patients were injected 0.3ml MMR vaccine whereas in Group B, 25 patients were injected 0.5ml Vitamin D injection after achieving anaesthesia with 0.2ml injection Lignocaine into the largest wart at 2 weeks interval until complete clearance or for maximum of 3 injections whichever was earlier. Patients were followed up fortnightly for 12 weeks. In Group A, 19 (76%) patients showed Grade IV, 2 (8%) patients had Grade III, 3 (12%) patients had GII and only 1 (4%) patient had Grade I improvement. In Group B on the other hand, 15 (60%) patients showed Grade IV, 4 (16%) patients had GIII, 4 (16%) patients had Grade II and 2 (8%) patients had Grade I improvement. None of the patients developed new lesions in both groups. Both the immunotherapeutic treatments are safe, economic and less traumatic to the patients as compared to the destructive procedures for the treatment of warts.

scholarly journals Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study

Cancers ◽  
2021 ◽  
Vol 13 (18) ◽  
pp. 4584
Author(s):  
Yen-Yang Chen ◽  
Chao-Long Chen ◽  
Chih-Che Lin ◽  
Chih-Chi Wang ◽  
Yueh-Wei Liu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Liver Transplantation ◽  
Progression Free Survival ◽  
Comparable Efficacy ◽  
Control Group ◽  
Efficacy And Safety ◽  
Free Survival ◽  
Significant Difference ◽  
The Difference

Tumor recurrence is the most common cause of death in hepatocellular carcinoma (HCC) patients who received liver transplantation (LT). Recently, lenvatinib was approved for the systemic treatment of unresectable HCC patients; however, the role of lenvatinib in HCC patients after LT remains unclear. There were 56 patients with recurrent HCC after LT from 2008 to 2018 in our institute, and 10 patients who received lenvatinib were identified. Additionally, to understand the difference in the clinical impact of lenvatinib in the LT and non-LT settings, 25 HCC patients without LT who underwent lenvatinib treatment were identified from our HCC database and regarded as the control group. In the LT group, partial response was 20% and stable disease was 50%, resulting in a disease control rate of 70%; the median progression-free survival (PFS), time to treatment failure (TTF) and overall survival (OS) were 3.7, 3.6 and 16.4 months, respectively. Adverse events (AEs) were predominantly grade 1–2 in severity, and the majority of patients tolerated the side effects. There was no significant difference in PFS/OS, and we observed a similar pattern of AEs between these two groups. Our study confirms the comparable efficacy and safety of lenvatinib in HCC patients with LT and non-LT in clinical practice.

Sign in / Sign up

Export Citation Format

Share Document